A detailed history of Values First Advisors, Inc. transactions in Argenx Se stock. As of the latest transaction made, Values First Advisors, Inc. holds 1,691 shares of ARGX stock, worth $737,005. This represents 0.39% of its overall portfolio holdings.

Number of Shares
1,691
Previous 2,061 17.95%
Holding current value
$737,005
Previous $784,000 15.18%
% of portfolio
0.39%
Previous 0.48%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$356.95 - $413.29 $132,071 - $152,917
-370 Reduced 17.95%
1,691 $665,000
Q4 2023

Jan 18, 2024

SELL
$338.91 - $506.01 $338,232 - $504,997
-998 Reduced 32.63%
2,061 $784,000
Q3 2023

Nov 08, 2023

BUY
$369.35 - $548.43 $120,777 - $179,336
327 Added 11.97%
3,059 $1.5 Million
Q2 2023

Aug 02, 2023

BUY
$360.14 - $422.58 $6,842 - $8,029
19 Added 0.7%
2,732 $1.06 Million
Q1 2023

May 15, 2023

BUY
$334.23 - $403.65 $80,215 - $96,876
240 Added 9.7%
2,713 $1.01 Million
Q4 2022

Jan 20, 2023

BUY
$342.17 - $402.31 $38,323 - $45,058
112 Added 4.74%
2,473 $0
Q3 2022

Dec 02, 2022

SELL
$343.2 - $395.75 $276,619 - $318,974
-806 Reduced 25.45%
2,361 $834,000
Q2 2022

Jul 20, 2022

BUY
$269.58 - $378.88 $29,653 - $41,676
110 Added 3.6%
3,167 $1.2 Million
Q1 2022

May 03, 2022

BUY
$254.45 - $351.06 $359,792 - $496,398
1,414 Added 86.06%
3,057 $964,000
Q4 2021

Mar 10, 2022

BUY
$272.01 - $353.03 $446,912 - $580,028
1,643 New
1,643 $576,000
Q3 2021

Nov 15, 2022

SELL
$295.0 - $350.58 $481,735 - $572,497
-1,633 Reduced 51.56%
1,534 $463,000
Q3 2020

Nov 15, 2022

SELL
$215.51 - $272.51 $738,768 - $934,164
-3,428 Closed
0 $0
Q2 2020

Nov 15, 2022

SELL
$127.44 - $232.72 $161,339 - $294,623
-1,266 Reduced 26.97%
3,428 $772,000
Q1 2020

Jan 09, 2023

BUY
$108.83 - $165.23 $186,425 - $283,038
1,713 Added 72.55%
4,074 $537 Million
Q4 2019

Nov 15, 2022

BUY
$106.59 - $164.21 $162,762 - $250,748
1,527 Added 48.22%
4,694 $754,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $24.1B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Values First Advisors, Inc. Portfolio

Follow Values First Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Values First Advisors, Inc. with notifications on news.